DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function
Madurka et al., Infection, doi:10.1007/s15010-022-01904-w
https://c19early.org/madurka.html